GENUS

Genus reported an adjusted pre-tax profit of £100.2m and adjusted EPS of 110.3p for H2 2026—both up 35%—with free cash flow of £62m. Reported revenue fell 2% to £658.1m, mainly due to the deconsolidation of PIC China. The company expects moderate profit growth in 2027, weighted to the second half, and announced a 10% dividend increase to 35.2p plus a £60m share buyback programme. Despite improved profitability, the stock fell 6.65% pre-market as investors weighed the revenue decline, the H2‑weighted outlook and regional headwinds more heavily. » Więcej na de.investing.com

Genus shares fell 6.5% after preliminary results for 2026 showed adjusted revenue down 2% to £658.1m, missing consensus. The decline in revenue was mainly due to the deconsolidation of PIC China following the formation of a joint venture with Beijing Capital Agribusiness. Positive: adjusted operating profit rose 25% to £116.0m and adjusted pre-tax profit rose 35% to £100.2m, supported by strong PIC growth and a £5.6m milestone payment. Genus announced a £60m share buyback programme but warned adjusted pre-tax earnings for 2027 are likely to be weighted heavily to the second half due to disease-related issues in North American pig production and lower hog and milk prices. » Więcej na de.investing.com

Genus forecasts an adjusted pre-tax profit of around £98m for fiscal 2026, beating consensus estimates. The positive revision reflects a stronger-than-expected second half, with robust growth in the pig genetics business (PIC) in Asia and Latin America and double-digit profit growth at the cattle genetics division (ABS) thanks to the Value Acceleration Programme. The company also reports very strong cash conversion, material free cash flow growth and a strengthened balance sheet heading into FY27. The shares rose sharply intraday and closed well above the prior level. » Więcej na de.investing.com